Algert Global LLC purchased a new position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 62,129 shares of the company's stock, valued at approximately $662,000.
A number of other large investors have also recently made changes to their positions in CERT. Barclays PLC grew its position in shares of Certara by 198.3% in the 3rd quarter. Barclays PLC now owns 70,525 shares of the company's stock worth $825,000 after buying an additional 46,880 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Certara by 442.2% in the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company's stock worth $90,000 after buying an additional 6,868 shares during the last quarter. Kopion Asset Management LLC grew its position in shares of Certara by 46.0% in the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company's stock worth $5,918,000 after buying an additional 175,005 shares during the last quarter. Blue Trust Inc. grew its position in shares of Certara by 20.9% in the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after buying an additional 822 shares during the last quarter. Finally, KBC Group NV grew its position in shares of Certara by 64.1% in the 4th quarter. KBC Group NV now owns 7,998 shares of the company's stock worth $85,000 after buying an additional 3,125 shares during the last quarter. 73.96% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on CERT. Stephens reiterated an "overweight" rating and issued a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. William Blair restated a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. TD Cowen assumed coverage on Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 price target on the stock. Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $11.00 to $14.00 in a research report on Thursday. Finally, KeyCorp lifted their price target on Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.67.
Get Our Latest Analysis on Certara
Certara Stock Up 0.9%
Shares of NASDAQ:CERT opened at $11.98 on Monday. The stock has a fifty day simple moving average of $11.67 and a two-hundred day simple moving average of $11.69. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of -59.90, a PEG ratio of 9.29 and a beta of 1.57. Certara, Inc. has a 12-month low of $8.64 and a 12-month high of $17.76. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.
Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. The business had revenue of $106.00 million during the quarter, compared to analysts' expectations of $104.44 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.10 earnings per share. On average, research analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.
About Certara
(
Free Report)
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Further Reading
Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Certara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.
While Certara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
